Company Profile

Elegen Corporation
Profile last edited on: 2/25/21      CAGE: 7XQ63      UEI: TM9HBLXBWML6

Business Identifier: Synthetic DNA for synthetic biology industry
Year Founded
2017
First Award
2020
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

MBC Biolabs 733 Industrial Road
San Carlos, CA 94070
   (650) 597-2248
   info@elegenbio.com
   www.elegenbio.com
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

As the synthetic biology revolution gathers momentum, it is projected that the process will spawn new applications, new markets and very different business models. Elegen management project that those rapid and in-dpeth changes revolution will be driven in some measure by new technologies that enable DNA writing to be at speed and at scale. In this context, Elegen is structured around creating a suite of ground-breaking technologies designed to support and enable sythetic biology to achieve DNA writing at high speed, lower cost, and better quality. In the Food and agricultural space that means creating sustainable, abundant food sources. In the chemicals space, enzymatic chemistry created new compounds without human assistance. Today the effort is to tap the world's oldest green chemical manufacturing process and enable creation of more new chemicals. .. while in the arena of new materials - petrochemical based polymers to clothing - synthetic biology has the power to re-create our everyday materials in a more green and sustainable way.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 2 NIH $1,999,951
Project Title: Novel Microfluidic Platform for Versatile, Fast, Low-Cost DNA Synthesis and Assembly

Key People / Management

  Matthew Hill -- Founder and CEO

  Dan La Caze -- Chief Business Officer

  Marc Unger -- CSO

Company News

There are no news available.